# Black Diamond Therapeutics, Inc.: financial statements, quarterly

BDTX · Nasdaq · CIK 1701541 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bdtx.md) · [Financials](/companies/bdtx/financials.md) · [Filings](/companies/bdtx/filings.md) · [Insiders](/companies/bdtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bdtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001701541-25-000022.md) | [0.0](/filings/0001701541-25-000030.md) | [0.0](/filings/0001701541-25-000039.md) | [0.0 d](/filings/0001701541-26-000009.md) | [70.0](/filings/0001701541-26-000017.md) | [0.0](/filings/0001701541-26-000025.md) | [0.0](/filings/0001701541-25-000039.md) | [0.0 d](/filings/0001701541-26-000009.md) | [0.0](/filings/0001701541-26-000017.md) | [0.0](/filings/0001701541-26-000025.md) |
| Research and development | $m | [16.2](/filings/0001701541-24-000042.md) | [15.3 d](/filings/0001701541-25-000016.md) | [13.5](/filings/0001701541-25-000022.md) | [12.6](/filings/0001701541-25-000030.md) | [12.9](/filings/0001701541-25-000039.md) | [12.3 d](/filings/0001701541-26-000009.md) | [10.5](/filings/0001701541-26-000017.md) | [9.3](/filings/0001701541-26-000025.md) | [7.4](/filings/0001701541-25-000039.md) | [6.3 d](/filings/0001701541-26-000009.md) | [7.0](/filings/0001701541-26-000017.md) | [7.4](/filings/0001701541-26-000025.md) |
| Operating income | $m | [(24.0)](/filings/0001701541-24-000042.md) | [(20.9) d](/filings/0001701541-25-000016.md) | [(20.2)](/filings/0001701541-25-000022.md) | [(22.1)](/filings/0001701541-25-000030.md) | [(18.1)](/filings/0001701541-25-000039.md) | [(18.3) d](/filings/0001701541-26-000009.md) | [54.5](/filings/0001701541-26-000017.md) | [(13.4)](/filings/0001701541-26-000025.md) | [(11.0)](/filings/0001701541-25-000039.md) | [(17.6) d](/filings/0001701541-26-000009.md) | [(11.3)](/filings/0001701541-26-000017.md) | [(12.1)](/filings/0001701541-26-000025.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001701541-25-000022.md) | [0.0 d](/filings/0001701541-25-000030.md) | not reported | not reported | not reported | not reported |
| Net income | $m | [(23.0)](/filings/0001701541-24-000042.md) | [(19.4) d](/filings/0001701541-25-000016.md) | [(18.2)](/filings/0001701541-25-000039.md) | [(19.9)](/filings/0001701541-25-000039.md) | [(15.6)](/filings/0001701541-25-000039.md) | [(16.0) d](/filings/0001701541-26-000009.md) | [56.5](/filings/0001701541-26-000025.md) | [(10.6)](/filings/0001701541-26-000025.md) | [(8.5)](/filings/0001701541-25-000039.md) | [(15.1) d](/filings/0001701541-26-000009.md) | [(9.0)](/filings/0001701541-26-000025.md) | [(9.9)](/filings/0001701541-26-000025.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0001701541-24-000042.md) | not reported | [(0.35)](/filings/0001701541-25-000022.md) | [(0.36)](/filings/0001701541-25-000030.md) | [(0.28)](/filings/0001701541-25-000039.md) | not reported | [0.98](/filings/0001701541-26-000017.md) | [(0.19)](/filings/0001701541-26-000025.md) | [(0.15)](/filings/0001701541-25-000039.md) | not reported | [(0.16)](/filings/0001701541-26-000017.md) | [(0.17)](/filings/0001701541-26-000025.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0001701541-24-000042.md) | not reported | [(0.35)](/filings/0001701541-25-000022.md) | [(0.36)](/filings/0001701541-25-000030.md) | [(0.28)](/filings/0001701541-25-000039.md) | not reported | [1.00](/filings/0001701541-26-000017.md) | [(0.19)](/filings/0001701541-26-000025.md) | [(0.15)](/filings/0001701541-25-000039.md) | not reported | [(0.16)](/filings/0001701541-26-000017.md) | [(0.17)](/filings/0001701541-26-000025.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [58.0](/filings/0001701541-24-000042.md) | [56.2](/filings/0001701541-25-000016.md) | [25.4](/filings/0001701541-25-000022.md) | [32.8](/filings/0001701541-25-000030.md) | [23.4](/filings/0001701541-25-000039.md) | [36.4](/filings/0001701541-26-000009.md) | [98.4](/filings/0001701541-26-000017.md) | [30.0](/filings/0001701541-26-000025.md) | [30.9](/filings/0001701541-25-000039.md) | [21.0](/filings/0001701541-26-000025.md) | [30.1](/filings/0001701541-26-000017.md) | [19.2](/filings/0001701541-26-000025.md) |
| Current assets | $m | [147](/filings/0001701541-23-000047.md) | [134](/filings/0001701541-25-000016.md) | [119](/filings/0001701541-24-000022.md) | [127](/filings/0001701541-24-000030.md) | [116](/filings/0001701541-24-000042.md) | [101](/filings/0001701541-26-000009.md) | [156](/filings/0001701541-25-000022.md) | [147](/filings/0001701541-25-000030.md) | [139](/filings/0001701541-25-000039.md) | [132](/filings/0001701541-26-000025.md) | [123](/filings/0001701541-26-000017.md) | [115](/filings/0001701541-26-000025.md) |
| Total assets | $m | [172](/filings/0001701541-23-000047.md) | [159](/filings/0001701541-25-000016.md) | [143](/filings/0001701541-24-000022.md) | [150](/filings/0001701541-24-000030.md) | [138](/filings/0001701541-24-000042.md) | [123](/filings/0001701541-26-000009.md) | [176](/filings/0001701541-25-000022.md) | [166](/filings/0001701541-25-000030.md) | [158](/filings/0001701541-25-000039.md) | [143](/filings/0001701541-26-000025.md) | [133](/filings/0001701541-26-000017.md) | [125](/filings/0001701541-26-000025.md) |
| Current liabilities | $m | [15.1](/filings/0001701541-23-000047.md) | [19.6](/filings/0001701541-25-000016.md) | [16.9](/filings/0001701541-24-000022.md) | [18.4](/filings/0001701541-24-000030.md) | [20.8](/filings/0001701541-24-000042.md) | [20.6](/filings/0001701541-26-000009.md) | [16.8](/filings/0001701541-25-000022.md) | [16.8](/filings/0001701541-25-000030.md) | [15.5](/filings/0001701541-25-000039.md) | [15.7](/filings/0001701541-26-000025.md) | [14.5](/filings/0001701541-26-000017.md) | [15.8](/filings/0001701541-26-000025.md) |
| Total liabilities | $m | [38.1](/filings/0001701541-23-000047.md) | [41.8](/filings/0001701541-25-000016.md) | [38.2](/filings/0001701541-24-000022.md) | [39.0](/filings/0001701541-24-000030.md) | [40.5](/filings/0001701541-24-000042.md) | [39.4](/filings/0001701541-26-000009.md) | [34.7](/filings/0001701541-25-000022.md) | [33.8](/filings/0001701541-25-000030.md) | [31.6](/filings/0001701541-25-000039.md) | [30.8](/filings/0001701541-26-000025.md) | [28.6](/filings/0001701541-26-000017.md) | [28.9](/filings/0001701541-26-000025.md) |
| Shareholders' equity | $m | [134](/filings/0001701541-24-000042.md) | [117](/filings/0001701541-26-000009.md) | [104](/filings/0001701541-25-000039.md) | [111](/filings/0001701541-25-000039.md) | [97.4](/filings/0001701541-25-000039.md) | [83.3](/filings/0001701541-26-000025.md) | [142](/filings/0001701541-26-000025.md) | [133](/filings/0001701541-26-000025.md) | [126](/filings/0001701541-25-000039.md) | [112](/filings/0001701541-26-000025.md) | [104](/filings/0001701541-26-000025.md) | [96.1](/filings/0001701541-26-000025.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.4) d](/filings/0001701541-24-000042.md) | [(14.0) d](/filings/0001701541-25-000016.md) | [(21.2)](/filings/0001701541-25-000022.md) | [(14.7) d](/filings/0001701541-25-000030.md) | [(11.3) d](/filings/0001701541-25-000039.md) | [(15.1) d](/filings/0001701541-26-000009.md) | [53.4](/filings/0001701541-26-000017.md) | [(9.2) d](/filings/0001701541-26-000025.md) | [(7.9) d](/filings/0001701541-25-000039.md) | [(6.8) d](/filings/0001701541-26-000009.md) | [(10.2)](/filings/0001701541-26-000017.md) | [(8.0) d](/filings/0001701541-26-000025.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001701541-24-000042.md) | [0.0 d](/filings/0001701541-25-000016.md) | not reported | not reported | not reported | [0.0 d](/filings/0001701541-25-000016.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.3](/filings/0001701541-23-000047.md) | [36.5](/filings/0001701541-24-000022.md) | [36.5](/filings/0001701541-24-000030.md) | [50.9](/filings/0001701541-24-000042.md) | [51.8](/filings/0001701541-25-000022.md) | [55.2](/filings/0001701541-25-000030.md) | [56.5](/filings/0001701541-25-000039.md) | [57.7](/filings/0001701541-26-000017.md) | [56.8](/filings/0001701541-26-000025.md) | [56.9](/filings/0001701541-25-000039.md) | [57.2](/filings/0001701541-26-000017.md) | [57.4](/filings/0001701541-26-000025.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 57,453,747 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001701541-26-000025.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.